Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3377540 | 0.91 | HDAC1 (0.45) | F10MAPTKDM4EMAPK1ACHE | |
| SCHEMBL13069668 | 0.90 | F10 (0.44) | F10MAPTKDM4EMAPK1ACHE | |
| SCHEMBL5781951 | 0.90 | F10 (0.51) | F10MAPTKDM4EMAPK1ACHE | |
| SCHEMBL5779826 | 0.89 | F10 (0.48) | F10MAPTKDM4EMAPK1ACHE | |
| SCHEMBL5781766 | 0.89 | F10 (0.50) | F10MAPTKDM4EMAPK1ACHE | |
| SCHEMBL5779457 | 0.89 | F10 (0.50) | F10MAPTKDM4EMAPK1ACHE | |
| SCHEMBL1243695 | 0.89 | F10 (0.48) | F10MAPTKDM4EMAPK1ALDH1A1 | |
| SCHEMBL5785214 | 0.88 | F10 (0.51) | F10MAPTKDM4EMAPK1ACHE | |
| SCHEMBL5781838 | 0.87 | HDAC1 (0.47) | F10MAPTKDM4EMAPK1ACHE | |
| SCHEMBL6402784 | 0.87 | F10 (0.52) | F10MAPTKDM4EMAPK1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029586-B1 | ISOINDOLIN-1-ONE-, ISOINDOLIN-3-ONE- AND ISOINDOLIN-1,3-DIONE-DERIVATIVES AND USE THEREOF | BAYER SCHERING PHARMA AG (DE) | 2010-11-24 | — | — | EP | disclosed |
| US-20100010060-A1 | Isoindolin-1-One-, Isoindolin-3-One- and Isoindolin-1,3-Dione-Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2010-01-14 | — | — | US | disclosed |
| US-20100010060-A1 | Isoindolin-1-One-, Isoindolin-3-One- and Isoindolin-1,3-Dione-Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2010-01-14 | — | — | US | disclosed |
| US-20100010060-A1 | Isoindolin-1-One-, Isoindolin-3-One- and Isoindolin-1,3-Dione-Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2010-01-14 | — | — | US | disclosed |
| EP-2029582-A1 | ISOINDOLIN-1-ONE-, ISOINDOLIN-3-ONE- AND ISOINDOLIN-1,3-DIONE-DERIVATIVES AND USE THEREOF | Bayer HealthCare AG (DE) | 2009-03-04 | — | — | EP | disclosed |
| EP-2029586-A1 | ISOINDOLIN-1-ONE-, ISOINDOLIN-3-ONE- AND ISOINDOLIN-1,3-DIONE-DERIVATIVES AND USE THEREOF | Bayer HealthCare AG (DE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007137790-A1 | ISOINDOLIN-1-ONE-, ISOINDOLIN-3-ONE- AND ISOINDOLIN-1,3-DIONE-DERIVATIVES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007137800-A1 | ISOINDOLIN-1-ONE-, ISOINDOLIN-3-ONE- AND ISOINDOLIN-1,3-DIONE-DERIVATIVES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007137800-A1 | ISOINDOLIN-1-ONE-, ISOINDOLIN-3-ONE- AND ISOINDOLIN-1,3-DIONE-DERIVATIVES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010060-A1 | Isoindolin-1-One-, Isoindolin-3-One- and Isoindolin-1,3-Dione-Derivatives and Use Thereof | ICAM1, SERPINC1, TFPI2 | F10 264/4885MAPT 3472/4885KDM4E 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.